Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
Thirty-nine isolates of Cryptococcus neoformans, nineteen serotype AD and twenty serotype BC, were assayed for susceptibility to eight antifungal agents using an in vitro agar dilution assay. Media employed were Kimmig agar and yeast nitrogen base supplemented with 10% glucose. The antifungal agents used were ketoconazole, amphotericin B, 5-fluorocytosine, nystatin, miconazole, BAY N 7133, ICI 153,066, and itraconazole. No clinically significant differences in vitro minimum inhibitory concentrations were detected between serotypes AD and BC against any of the compounds tested. An adverse medium effect was observed in two of the assays, but the outcome of the AD/BC comparison was not affected. This is the first report in which the in vitro antifungal susceptibilities of Cryptococcus neoformans serotypes are analyzed.
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D003454:Cryptococcus / Q000187:drug effects*; D003455:Cryptococcus neoformans / Q000145:classification / Q000187:drug effects*; D005437:Flucytosine / Q000494:pharmacology; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000494:pharmacology; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000494:pharmacology; D012703:Serotyping; D014230:Triazoles / Q000494:pharmacology
D000935:Antifungal Agents; D014230:Triazoles; D009761:Nystatin; D017964:Itraconazole; C040032:ICI 153066; D008825:Miconazole; D000666:Amphotericin B; C037494:vibunazole; D005437:Flucytosine; D007654:Ketoconazole